FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256388775> ?p ?o ?g. }

• W4256388775 endingPage "1985" @default.
• W4256388775 startingPage "1985" @default.
• W4256388775 abstract "Abstract Background Bone marrow fibrosis (BMF) is observed in 10-20% of patients diagnosed with MDS. A study conducted at the University of Pavia, Italy evaluated 180 cases of MDS with varying grades of BMF and found that the presence of grade 2-3 BMF in MDS (graded by European classification) was associated with worse outcomes, especially in patients with lower risk MDS, however there remains little data pertaining to the treatment and outcomes in the MDS-F patient population. The primary objective of this study is to examine a large MDS patient population to further determine the relationship between BMF and survival outcomes in the context of new risk stratification models. Methods All bone marrow aspirate and biopsy reports, obtained at the time of diagnosis or prior to any therapy, in the Moffitt Cancer Center MDS database were reviewed and the degree of BMF was determined using the European classification system. Patients with less than 5% myeloblasts and grade 2 or 3 BMF were identified and these bone marrow aspirate and biopsies were reviewed by two hematopathologists (LZ and JMB) to confirm the grade of fibrosis reported. Patients were then divided into two groups: grade 0-2 BMF and severe BMF (grade 3). These two groups were compared to evaluate differences in clinical characteristics, response to treatment and survival. NexGen sequencing was available for 251 patients and distribution of acquired somatic mutations were compared between grade 0-2 BMF and grade 3 BMF. Results There were 2357 cases included in this analysis of which 2237 (95%) were determined to have grade 0-2 BMF and 120 (5 %) to have grade 3 BMF. Table-1 summarizes baseline characteristics. There was no statistical difference in age at diagnosis, gender, or race. A greater percentage of patients with severe BMF (39%) met the criteria for poor/very poor IPSS-R score category than patients with grade 0-2 BMF (29%), p = 0.011. Complex karyotype was observed more frequently among patients with severe fibrosis (23% versus 15%, p = 0.031). Patients with severe BMF also had a higher incidence of elevated LDH (51%) than patients with grade 0-2 BMF (33%), P < 0.005. The median overall survival (OS) was 38.7 months (mo) for grade 0-2 BMF and 23.1mo for grade 3 BMF, p < 0.005. When examined by revised IPSS (R-IPSS), severe BMF only impacted OS among the lower risk group. The median OS in patients with very low/low R-IPSS risk was 47mo in patients with severe BMF compared to 77 for those with grade 0-2 BMF, p = 0.015. In multivariable analysis, adjusting for age and R-IPSS, severe BMF was independently associated with inferior OS (HR 1.7, P 0.01). The rate of AML transformation was 28% in both the severe and grade 0-2 BMF groups, p = 0.98. Eighty patients with severe BMF were treated with hypomethylating agents (HMA). The overall response, by IWG 2006 criteria, of HI or better was 30% among patients with severe BMF compared to 32% of patients with grade 0-2 BMF, p 0.4. Among patients with severe BMF treated with lenalidomide (n=30), 25% of patients had HI response compared to 16% in patients with grade 0-2 BMF, p 0.9. The median OS for the 100 patients with severe BMF who did not undergo allogenic SCT was 23mo compared to 30mo for the 19 patients with severe BMF who did undergo allogenic SCT, p 0.29 Among somatic gene mutations, SF3B1 mutation was observed in 14% of grade 0-2 and 0% of grade 3 fibrosis. However, SRSF2 was present in 35.7% of patients with grade 3 fibrosis and only 9.7% of patients with grade 0-2 BMF, p .009. There was no statistically significant difference in the rate of occurrence of TP53 and RUNX1 mutations between the grade 0-2 BMF and the grade 3 BMF groups. In addition, there was no significant difference in the rate of occurrence of JAK2 mutation across the two groups. (table-2) Conclusions In our MDS cohort, only the presence of severe BMF (grade 3) was associated with worse outcome with reduced overall survival namely among patients with very low/low R-IPSS disease, whereas BMF grade did not impact response to HMA or lenalidomide treatment. SRSF2 gene mutation occurred with greater frequency among patients with severe fibrosis. Table 1 Baseline characteristics Table 1. Baseline characteristics Table 2 Acquired Somatic Mutations Table 2. Acquired Somatic Mutations Disclosures Sweet: Incyte Corporation: Research Funding; Ariad: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Pfizer: Speakers Bureau; Karyopharm: Honoraria, Research Funding. Bennett:Celgne: Membership on an entity's Board of Directors or advisory committees. Komrokji:Incyte: Consultancy; Novartis: Consultancy, Speakers Bureau; Boehringer-Ingelheim: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W4256388775 created "2022-05-12" @default.
• W4256388775 creator A5010075752 @default.
• W4256388775 creator A5020819343 @default.
• W4256388775 creator A5029369362 @default.
• W4256388775 creator A5041443589 @default.
• W4256388775 creator A5041754278 @default.
• W4256388775 creator A5057933586 @default.
• W4256388775 creator A5060287712 @default.
• W4256388775 creator A5065804627 @default.
• W4256388775 creator A5066001318 @default.
• W4256388775 creator A5083228843 @default.
• W4256388775 creator A5086317353 @default.
• W4256388775 date "2016-12-02" @default.
• W4256388775 modified "2023-09-26" @default.
• W4256388775 title "Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome" @default.
• W4256388775 doi "https://doi.org/10.1182/blood.v128.22.1985.1985" @default.
• W4256388775 hasPublicationYear "2016" @default.
• W4256388775 type Work @default.
• W4256388775 citedByCount "0" @default.
• W4256388775 crossrefType "journal-article" @default.
• W4256388775 hasAuthorship W4256388775A5010075752 @default.
• W4256388775 hasAuthorship W4256388775A5020819343 @default.
• W4256388775 hasAuthorship W4256388775A5029369362 @default.
• W4256388775 hasAuthorship W4256388775A5041443589 @default.
• W4256388775 hasAuthorship W4256388775A5041754278 @default.
• W4256388775 hasAuthorship W4256388775A5057933586 @default.
• W4256388775 hasAuthorship W4256388775A5060287712 @default.
• W4256388775 hasAuthorship W4256388775A5065804627 @default.
• W4256388775 hasAuthorship W4256388775A5066001318 @default.
• W4256388775 hasAuthorship W4256388775A5083228843 @default.
• W4256388775 hasAuthorship W4256388775A5086317353 @default.
• W4256388775 hasConcept C126322002 @default.
• W4256388775 hasConcept C141071460 @default.
• W4256388775 hasConcept C142724271 @default.
• W4256388775 hasConcept C143998085 @default.
• W4256388775 hasConcept C151730666 @default.
• W4256388775 hasConcept C2775934546 @default.
• W4256388775 hasConcept C2779343474 @default.
• W4256388775 hasConcept C2780007613 @default.
• W4256388775 hasConcept C2780817109 @default.
• W4256388775 hasConcept C2908647359 @default.
• W4256388775 hasConcept C71924100 @default.
• W4256388775 hasConcept C86803240 @default.
• W4256388775 hasConcept C99454951 @default.
• W4256388775 hasConceptScore W4256388775C126322002 @default.
• W4256388775 hasConceptScore W4256388775C141071460 @default.
• W4256388775 hasConceptScore W4256388775C142724271 @default.
• W4256388775 hasConceptScore W4256388775C143998085 @default.
• W4256388775 hasConceptScore W4256388775C151730666 @default.
• W4256388775 hasConceptScore W4256388775C2775934546 @default.
• W4256388775 hasConceptScore W4256388775C2779343474 @default.
• W4256388775 hasConceptScore W4256388775C2780007613 @default.
• W4256388775 hasConceptScore W4256388775C2780817109 @default.
• W4256388775 hasConceptScore W4256388775C2908647359 @default.
• W4256388775 hasConceptScore W4256388775C71924100 @default.
• W4256388775 hasConceptScore W4256388775C86803240 @default.
• W4256388775 hasConceptScore W4256388775C99454951 @default.
• W4256388775 hasIssue "22" @default.
• W4256388775 hasLocation W42563887751 @default.
• W4256388775 hasOpenAccess W4256388775 @default.
• W4256388775 hasPrimaryLocation W42563887751 @default.
• W4256388775 hasRelatedWork W1971262694 @default.
• W4256388775 hasRelatedWork W2004879554 @default.
• W4256388775 hasRelatedWork W2160204079 @default.
• W4256388775 hasRelatedWork W2339687729 @default.
• W4256388775 hasRelatedWork W2359678758 @default.
• W4256388775 hasRelatedWork W2395291858 @default.
• W4256388775 hasRelatedWork W2404213257 @default.
• W4256388775 hasRelatedWork W3031043207 @default.
• W4256388775 hasRelatedWork W35207654 @default.
• W4256388775 hasRelatedWork W2338139283 @default.
• W4256388775 hasVolume "128" @default.
• W4256388775 isParatext "false" @default.
• W4256388775 isRetracted "false" @default.
• W4256388775 workType "article" @default.